-transparent.png){kind=logo}
To determine whether hemodynamic effects of isosorbide dinitrate (ISDN) diminish and disappear during sustained administration, nine patients with recent myocardial infarction received 10 mg of ISDN intravenously before and 1, 4, 12, 24, and 48 weeks after sustained oral administration of 20 mg of the slow-release form of ISDN four times daily. Blood pressure always decreased after intravenous ISDN; the decrease tended to be diminished when preceded by oral ISDN, but no further attenuation in blood pressure was noted. The decrease in blood pressure was associated with consistent and nonsignificant increases in heart rate after intravenous ISDN. Plasma ISDN levels were not affected by prior oral ISDN. Plasma isosorbide 2-mononitrate and isosorbide 5-mononitrate levels were consistently higher when preceded by oral ISDN. The results suggest that the hemodynamic and metabolic properties of ISDN are preserved even after sustained therapy.
H Kumagae, and
Y Koiwaya, and
K Tanaka
September 1980,
La Nouvelle presse medicale,
H Kumagae, and
Y Koiwaya, and
K Tanaka
June 1982,
Journal of pharmaceutical sciences,
H Kumagae, and
Y Koiwaya, and
K Tanaka
January 1979,
Coeur et medecine interne,
H Kumagae, and
Y Koiwaya, and
K Tanaka
July 1983,
Journal of the American College of Cardiology,
H Kumagae, and
Y Koiwaya, and
K Tanaka
January 1985,
European journal of clinical pharmacology,
H Kumagae, and
Y Koiwaya, and
K Tanaka
February 1984,
The American journal of medicine,
H Kumagae, and
Y Koiwaya, and
K Tanaka
August 1984,
The American journal of cardiology,
H Kumagae, and
Y Koiwaya, and
K Tanaka
February 1977,
Circulation,
H Kumagae, and
Y Koiwaya, and
K Tanaka
January 1980,
Chest,
H Kumagae, and
Y Koiwaya, and
K Tanaka
November 1982,
Schweizerische medizinische Wochenschrift,
